Published in Clin Sci (Lond) on June 01, 2011
Renal autoregulation in health and disease. Physiol Rev (2015) 1.18
Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. PLoS One (2012) 0.90
Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Res Ther (2013) 0.88
Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol (2015) 0.80
Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One (2013) 0.79
Hemodynamics and function of resistance arteries in healthy persons and end stage renal disease patients. PLoS One (2014) 0.77
Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. Medicine (Baltimore) (2016) 0.76
Defining uremic arterial functional abnormalities in patients recently started on haemodialysis: combined in vivo and ex vivo assessment. PLoS One (2014) 0.75
Long chain n-3 polyunsaturated fatty acids and vascular function in patients with chronic kidney disease and healthy subjects: a cross-sectional and comparative study. BMC Nephrol (2016) 0.75
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int (2010) 3.53
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol (2008) 2.96
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol (2008) 2.44
Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2008) 2.42
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 2.17
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 2.09
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant (2002) 2.05
[In Process Citation]. Lakartidningen (2015) 2.01
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol (2009) 1.88
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. Nephrol Dial Transplant (2002) 1.82
Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial (2010) 1.82
Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol (2012) 1.80
Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int (2005) 1.80
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int (2006) 1.80
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol (2011) 1.77
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) 1.69
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant (2006) 1.65
The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant (2004) 1.62
Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.61
Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis (2005) 1.57
Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr (2007) 1.55
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis (2009) 1.54
Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med (2013) 1.47
Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. Obesity (Silver Spring) (2013) 1.47
Reduced oxidative power but unchanged antioxidative capacity in skeletal muscle from aged humans. Pflugers Arch (2003) 1.44
Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. J Ren Nutr (2012) 1.43
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. Blood Purif (2005) 1.40
Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle (2011) 1.39
[Ghrelin--new promising treatment in anorexia and catabolic conditions]. Lakartidningen (2010) 1.39
Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr (2008) 1.38
Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol (2009) 1.38
Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis (2008) 1.38
[Pre-eclampsia. A multi-organ disease which occurs in many pregnancies]. Lakartidningen (2006) 1.37
Derangements in mitochondrial metabolism in intercostal and leg muscle of critically ill patients with sepsis-induced multiple organ failure. Am J Physiol Endocrinol Metab (2006) 1.31
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int (2013) 1.31
Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr (2004) 1.30
Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis (2009) 1.28
Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant (2002) 1.24
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.22
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.22
Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens (2011) 1.21
Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis (2005) 1.17
High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med (2008) 1.17
Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int (2007) 1.16
Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Lond) (2007) 1.14
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
The role of oxidative stress in chronic kidney disease. Semin Dial (2009) 1.12
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant (2011) 1.12
Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr (2005) 1.11
Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.10
Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus (2009) 1.09
Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol (2003) 1.09
Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant (2010) 1.09
Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One (2013) 1.09
Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle (2013) 1.08
Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol (2009) 1.08
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol (2008) 1.08
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07
Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant (2004) 1.07
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol (2009) 1.06
Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int (2005) 1.03
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant (2008) 1.03
Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol (2011) 1.03
Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol (2008) 1.02
Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant (2003) 1.02
Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant (2009) 1.01
Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis (2005) 1.01
Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.01
Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant (2011) 1.00
Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int (2004) 1.00
Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int (2004) 1.00
Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol (2010) 1.00
Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. Nephrol Dial Transplant (2004) 0.99
Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant (2010) 0.99
Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant (2006) 0.99
Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant (2003) 0.99
Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int (2005) 0.98
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol (2007) 0.98
The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant (2003) 0.97
Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther (2003) 0.97
Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol (2011) 0.97
The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J Physiol (2006) 0.97